Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Vascular dementia is the second-most common form of dementia after Alzheimer’s. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

The combination of a recently approved blood test for the detection of Alzheimer’s disease, combined with two medications that slow the progression of the disease, is drastically improving outcomes ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Scientists hail ‘very exciting’ findings that explain why Alzheimer’s patients forget their loved ones, and say drugs are ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.